Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 1 (1)

Trial Status

Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT02863692Recruiting

Registry of the German CLL Study Group

NCT00462189Phase 1Unknown

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Showing all 2 trials

Research Network

Activity Timeline